# EP-100 Plus Paclitaxel Versus Paclitaxel Alone in Patients With Ovarian Cancer

> **NCT01485848** · PHASE2 · COMPLETED · sponsor: **Esperance Pharmaceuticals Inc** · enrollment: 49 (actual)

## Conditions studied

- Ovarian Cancer Recurrent

## Interventions

- **DRUG:** EP-100
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT01485848
- **Lead sponsor:** Esperance Pharmaceuticals Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-02
- **Primary completion:** 2014-05
- **Final completion:** 2014-05
- **Target enrollment:** 49 (ACTUAL)
- **Last updated:** 2014-06-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01485848

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01485848, "EP-100 Plus Paclitaxel Versus Paclitaxel Alone in Patients With Ovarian Cancer". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01485848. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*